Back to Directory Monica Lopez Email monica.c.lopez@viivhealthcare.com Institution ViiV Healthcare Request an Update Affiliated Studies IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number 38717 Research Area Treatment Study Status Withdrawn
IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number 38717 Research Area Treatment Study Status Withdrawn